Clinical Trial Update: Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update exploring optical imaging of PD-1/PD-L1 in locally advanced esophageal cancer using Durvalumab-680LT and Nivolumab-800CW.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Durvalumab-680LT (durvalumab-680LT)
• Nivolumab-800CW (Nivolumab)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Esophageal Cancer | Phase 1 | Status: NOT_YET_RECRUITING